BNP Paribas Financial Markets
RAPP

BNP Paribas Financial Markets’s Rapport Therapeutics RAPP Stock Holding History

BNP Paribas Financial Markets’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$919K Sell
22,055
-13,897
-39% -$511K ﹤0.01% 3374
2026
Q1 		$1.12M Buy
35,952
+23,599
+191% +$664K ﹤0.01% 3056
2025
Q4 		$375K Buy
12,353
+5,133
+71% +$142K ﹤0.01% 3725
2025
Q3 		$214K Buy
7,220
+5,259
+268% +$93.8K ﹤0.01% 3980
2025
Q2 		$22.3K Buy
1,961
+752
+62% +$7.98K ﹤0.01% 4550
2025
Q1 		$12.1K Sell
1,209
-203
-14% -$2.64K ﹤0.01% 4668
2024
Q4 		$25K Sell
1,412
-272
-16% -$6.03K ﹤0.01% 4667
2024
Q3 		$34.5K Buy
+1,684
New +$36.2K ﹤0.01% 3690

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BNP Paribas Financial Markets's RAPP Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Rapport Therapeutics (RAPP) stake by 39% in Q2 2026, selling an estimated $511K and leaving 22,055 shares worth $919K. The position accounts for ﹤0.01% of the portfolio, ranked #3374.

BNP Paribas Financial Markets first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.12M in Q1 2026. 146 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • BNP Paribas Financial Markets held 22,055 shares of Rapport Therapeutics worth $919K as of Q2 2026.
  • BNP Paribas Financial Markets sold 13,897 Rapport Therapeutics shares in Q2 2026, an estimated $511K.
  • Rapport Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3374 holding.
  • BNP Paribas Financial Markets first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • BNP Paribas Financial Markets's Rapport Therapeutics position peaked at $1.12M in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.